Phase 4 N=120 Randomized Treatment

Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist

Infertility

Bottom Line

View on ClinicalTrials.gov: NCT01607203 ↗

Enrolled (actual)

120

Serious AEs

0.0%

Results posted

Feb 2015

Primary outcome: Primary: MII Oocytes — 9.2; 10.3 cumulus oocyte complex

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Decapeptyl Daily (Drug); pregnyl (Drug)
Age: Pediatric, Adult
Sex: Female
Sponsor: AZ Jan Palfijn Gent
Primary completion: Dec 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY MII Oocytes	9.2; 10.3	—
SECONDARY Pregnancy Rate	28; 45	—
SECONDARY Patients With Cryopreserved Embryos	21; 33	0.04 sig

Summary

The purpose of this study is to see whether patients triggered with only human Chorion Gonadotropin (hCG) have higher number of Metaphase II oocytes (MII) and implantation rate than patients triggered with hCG combined with Gonadotropin Releasing Hormone (GnRH) agonist.

Eligibility Criteria

Inclusion Criteria

Intra-cytoplasmic sperm injection (ICSI) patients below 38 years
1,2 or 3 rd IVF-cycle

Exclusion Criteria

polycystic ovary syndrome (PCOS) patients
patients with endocrinological diseases or problems

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01607203). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.